EGFR and non-small cell lung carcinoma: Based on its high specificity [37,38,39,40], minimally invasive approach as well as a faster turn-around-time for reporting [27,28], several expert panels currently recommend that for patients with advanced NSCLC where tissue cannot be obtained or is insufficient for mutation testing, ctDNA may be used to identify EGFR mutations [43,44,45,46].